A history of the roles of cytochrome P450 enzymes in the toxicity of drugs

被引:0
作者
F. Peter Guengerich
机构
[1] Vanderbilt University School of Medicine,Department of Biochemistry
来源
Toxicological Research | 2021年 / 37卷
关键词
Cytochrome P450; Drugs; Toxicity; Reactive intermediates; Drug-drug interactions; Toxicophores;
D O I
暂无
中图分类号
学科分类号
摘要
The history of drug metabolism began in the 19th Century and developed slowly. In the mid-20th Century the relationship between drug metabolism and toxicity became appreciated, and the roles of cytochrome P450 (P450) enzymes began to be defined in the 1960s. Today we understand much about the metabolism of drugs and many aspects of safety assessment in the context of a relatively small number of human P450s. P450s affect drug toxicity mainly by either reducing exposure to the parent molecule or, in some cases, by converting the drug into a toxic entity. Some of the factors involved are enzyme induction, enzyme inhibition (both reversible and irreversible), and pharmacogenetics. Issues related to drug toxicity include drug–drug interactions, drug-food interactions, and the roles of chemical moieties of drug candidates in drug discovery and development. The maturation of the field of P450 and drug toxicity has been facilitated by advances in analytical chemistry, computational capability, biochemistry and enzymology, and molecular and cell biology. Problems still arise with P450s and drug toxicity in drug discovery and development, and in the pharmaceutical industry the interaction of scientists in medicinal chemistry, drug metabolism, and safety assessment is critical for success.
引用
收藏
页码:1 / 23
页数:22
相关论文
共 954 条
  • [21] Miller JA(1981)Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite Proc Natl Acad Sci USA 78 2545-2548
  • [22] Garfinkel D(2016)Assessment of protein binding of 5-hydroxythalidomide bioactivated in humanized mice with human P450 3A-chromosome or hepatocytes by two-dimensional electrophoresis/accelerator mass spectrometry Chem Res Toxicol 29 1279-1281
  • [23] Klingenberg M(2014)Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide Chem Res Toxicol 27 147-156
  • [24] Omura T(2012)In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK-NOG mice Chem Res Toxicol 25 274-276
  • [25] Sato R(2011)In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice Chem Res Toxicol 24 287-289
  • [26] Omura T(2010)Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate Chem Res Toxicol 23 1018-1024
  • [27] Sato R(2017)The dihydroxy metabolite of the teratogen thalidomide causes oxidative DNA damage Chem Res Toxicol 30 1622-1628
  • [28] Omura T(2010)Identification of a primary target of thalidomide teratogenicity Science 327 1345-1350
  • [29] Sato R(2005)Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study Hepatology 42 1364-1372
  • [30] Cooper DY(1973)Acetaminophen-induced hepatic necrosis. III. Cytochrome P-450-mediated covalent binding in vitro J Exp Pharmacol Ther 187 203-210